CMD takeaways: trials on track and cash runway extended
Yesterday, MoonLake held a CMD where it provided i) HS landscape recap post-AAD, ii) an update on the status of their phase 2 trials with sonelokimab (SLK) in HS and PSA and iii) a financial update, extending the cash runway. Overall, we remain bullish on the HS readout at the end of June as we bel
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.